Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
pharma · Diffuse Cutaneous Systemic Sclerosis · Myopia
Elan Pharmaceuticals
Elan Pharma International
Elan Pharmaceuticals drug portfolio — 26 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Treasury Building, Lower Grand Canal Street, Dublin 2, IE HQ
1969 Founded
792 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Treasury Building, Lower Grand Canal Street, Dublin 2, IE
- Founded
- 1969
- Employees
- 792
- Programs
- 18
- Drugs
- 26
- Patents
- 0
Elan Pharmaceuticals pipeline
Portfolio lens on 26 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Elan Pharmaceuticals drug portfolio — 26 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
atropine
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
imiquimod
Dermatologicals (D06)US regulatory status: approved. Molecular target: Toll-like receptor 7.
- Target
- Toll-like receptor 7
- Mechanism
- Toll-like receptor 7 agonist
-
inebilizumab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Elan Pharmaceuticals's portfolio. Molecular target: B-lymphocyte antigen CD19.
- Target
- B-lymphocyte antigen CD19
- Mechanism
- B-lymphocyte antigen CD19 binding agent
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
mannitol
Respiratory system (R05)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Elan Pharmaceuticals in public FDA and regional records. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor